Project Summary
Vasalgel is a new male contraceptive being developed by the Parsemus Foundation’s social venture, Revolution Contraceptives, to fill the need for a non-hormonal, long-acting, reversible male method.
- Despite currently available contraceptives, 85 million unintended pregnancies (40%) occur annually worldwide.
- Men currently have little choice when it comes to contraception. Vasectomy is considered permanent, and condoms have a high failure rate with typical use.
- While women have more options, many methods are discontinued due to side effects.
- Men and women are demanding more options for contraception, especially male methods.
- Research shows that about half of men surveyed would be willing to use a new male contraceptive.
- Long-acting, reversible, and non-hormonal methods are preferred.
- The Parsemus Foundation has supported the development of Vasalgel, a long-acting, non-hormonal male contraceptive that is designed to be reversible.
- Vasalgel blocks the flow of sperm from the body with an injection of a gel into the vas deferens.
- Revolution Contraceptives, the social venture company developing Vasalgel, believes in empowering men worldwide to better control their reproduction with a reliable, safe, cost-effective, and reversible contraceptive.
Project Topics
Vasalgel, a multi-year contraceptive
VasalgelTM is being developed as a long-acting, non-hormonal contraceptive with a significant advantage over vasectomy: it is likely to be more reversible. The procedure is similar to a no-scalpel vasectomy, except a gel is injected into the vas deferens (the tube the sperm swim through), rather than cutting the vas (as is done in vasectomy). If a man wishes to restore the flow of sperm, whether after months or years, the polymer would be dissolved and flushed out.
In early 2010, the Parsemus Foundation began developing Vasalgel as a new vas-occlusive polymer contraceptive. Revolution Contraceptives was created to bring the product to market. This social venture company’s mission is to empower men worldwide to better control their reproduction with a reliable, safe, cost-effective, and reversible contraceptive.
Stay engaged with Vasalgel
Contribute
- Support the development of Vasalgel by donating to help get it to market. Just direct your gift to Vasalgel and 100% of your donation goes toward Vasalgel development!
Stay Connected
- Follow Vasalgel’s progress on Facebook and Twitter, and join the Vasalgel email list to receive updates.
Visit the Revolution Contraceptives website
- Visit the Revolution Contraceptives website to get more information on Vasalgel.
Human Health News
Planning for new male contraceptives
Elaine Lissner, founder of the Parsemus Foundation, recently participated in an ideation workshop in San Francisco for the Male Contraceptive Initiative (MCI). The goal of
Announcing the new Revolution Contraceptives website
The Parsemus Foundation began working on a new male contraceptive called Vasalgel a number of years ago. In 2013, Revolution Contraceptives was formed as a
Vasalgel funding boosted by $200K grant from MCI
Revolution Contraceptives received a $200,000 grant from the Male Contraceptive Initiative (MCI) to advance Vasalgel towards human trials. The grant will support preclinical studies that
Androgens hold promise for breast cancer treatment
Androgens, such as testosterone, are commonly considered male hormones but they are also present in lower levels in women. Researchers from the University of Adelaide
Reproductive rights advance in Argentina
Years of grassroots efforts to support women’s reproductive rights was recently successful in legalizing abortion in Argentina. Argentina’s president, Alberto Fernández, was a supporter and
Veterinarians debate impact of spay/neuter
Recent publications by researchers at the University of California, Davis on the risks to dogs of joint disorders, cancers, and incontinence following spay or neuter
All progestins are not the same for menopausal hormone therapy
Hormone therapy alleviates symptoms of menopause, but fear of an increased risk of breast cancer deters some women and physicians from its use. Research has